Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and ...

Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...

Please provide your email address to receive an email when new articles are posted on . Retina specialists need to know when to consult with neuro-ophthalmology. The key to understanding when to ...

Please provide your email address to receive an email when new articles are posted on . “Things that can cause retinal disease can often cause neuro-ophthalmic disease, and that overlap is sometimes a ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.

Heidi Hernandez has earned a highly competitive residency at The Eye Institute of Salus University (TEI). The two-year neuro-ophthalmic disease residency accepts only one resident annually and is the ...